PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Drug Profile

PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Latest Information Update: 01 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anhui Kedgene Biotechnology
  • Developer Anhui Kedgene Biotechnology; Hangzhou Cancer Hospital
  • Class Antineoplastics; Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Programmed cell death-1 receptor antagonists; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Oesophageal cancer

Most Recent Events

  • 20 Mar 2017 Phase-II clinical trials in Oesophageal cancer (Metastatic disease, Second-line therapy or greater, Recurrent, Late-stage disease) in China (IV, Infusion) (NCT03081715)
  • 11 Mar 2017 Anhui Kedgene Biotechnology plans a phase II trial for Oesophageal cancer in China (NCT03081715)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top